ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.134+5G>A

dbSNP: rs80358038
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001010944 SCV001171209 pathogenic Hereditary cancer-predisposing syndrome 2021-06-11 criteria provided, single submitter clinical testing The c.134+5G>A intronic pathogenic mutation results from a G to A substitution 5 nucleotides after coding exon 2 in the BRCA1 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). One functional study found all substitutions at this nucleotide position are non-functional in a high-throughput, genome editing, haploid cell survival assay (Findlay GM et al. Nature, 2018 10;562:217-222). In addition, a variant at the same nucleotide position, BRCA1 c.134+5G>T, causes skipping of of coding exon 2 (also called exon 3 in the literature: Baert A et al. Hum. Mutat., 2018 04;39:515-526). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Invitae RCV001221249 SCV001393280 likely pathogenic Hereditary breast ovarian cancer syndrome 2023-10-22 criteria provided, single submitter clinical testing This sequence change falls in intron 3 of the BRCA1 gene. It does not directly change the encoded amino acid sequence of the BRCA1 protein. It affects a nucleotide within the consensus splice site. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with pancreatic ductal adenocarcinoma (PMID: 10923033, 30274973). ClinVar contains an entry for this variant (Variation ID: 91548). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects BRCA1 function (PMID: 30209399). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts the c.134+5G nucleotide in the BRCA1 gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 29280214, 30209399). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV003477477 SCV004222558 likely pathogenic not provided 2023-04-06 criteria provided, single submitter clinical testing This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, the variant has been reported in an individual affected with pancreatic cancer (PMID: 30274973 (2018)). Analysis of the variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant may affect proper BRCA1 mRNA splicing . The variant is predicted to interfere with normal BRCA1 mRNA splicing (personal communication Ambry Genetics (http://www.ambrygen.com/)), and a functional study described the variant as causing loss of function due to the lack of cell survival (PMID: 30209399 (2018)). In addition, a related G>T variant at this same position in the intron was shown to affect splicing (PMID: 29280214 (2018), 36446827 (2023)). Based on the available information, the c.134+5G>A variant is classified as likely pathogenic.
Sharing Clinical Reports Project (SCRP) RCV000077065 SCV000108862 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2009-07-17 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000077065 SCV000144420 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 1 2004-11-25 no assertion criteria provided clinical testing
Brotman Baty Institute, University of Washington RCV000077065 SCV001242403 not provided Breast-ovarian cancer, familial, susceptibility to, 1 no assertion provided in vitro

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.